Table 2.
Characteristics of patients treated exclusively with thrice weekly in-center hemodialysis in the first 91-day period after initiation of in-center hemodialysis by category of dialysis standard Kt/V
| Characteristic | Total | Category of Dialysis stdKt/V | ||
|---|---|---|---|---|
| <2.1 | 2.1 to <2.3 | ≥2.3 | ||
| N | 109,273 | 29,440 | 29,845 | 49,988 |
| Age, yr | 63±15 | 60±15 | 63±15 | 65±15 |
| Sex, % women | 43 | 27 | 36 | 57 |
| Body mass index, kg/m2 | 28±7 | 31±8 | 29±7 | 26±6 |
| Weekly treatment frequency | 3 (3–3) | 3 (3–3) | 3 (3–3) | 3 (3–3) |
| Mean treatment time, min | 212±23 | 205±25 | 211±23 | 215±22 |
| Weekly interdialytic weight gain, kg | 5.7±2.9 | 5.3±2.9 | 5.6±2.8 | 5.9±2.9 |
| Race, % | ||||
| White | 47 | 48 | 48 | 46 |
| Black | 31 | 35 | 32 | 29 |
| Asian | 3 | 2 | 3 | 4 |
| Hispanic | 15 | 12 | 14 | 17 |
| Other | 4 | 3 | 3 | 4 |
| Primary insurance, % | ||||
| Medicare | 54 | 49 | 53 | 56 |
| Medicaid | 6 | 8 | 7 | 7 |
| Other insurance | 40 | 43 | 40 | 37 |
| Access type, % | ||||
| CVC | 78 | 74 | 77 | 81 |
| AV fistula | 15 | 20 | 16 | 12 |
| AV graft | 4 | 3 | 4 | 5 |
| Unknown | 3 | 3 | 2 | 3 |
| Facility region, % | ||||
| Northeast | 13 | 11 | 13 | 13 |
| Midwesta | 18 | 18 | 19 | 18 |
| South | 43 | 41 | 43 | 44 |
| West | 25 | 28 | 25 | 24 |
| Coexisting illnesses, % | ||||
| Diabetes | 58 | 61 | 59 | 57 |
| Hypertension | 51 | 49 | 51 | 53 |
| Atherosclerotic heart diseasea | 14 | 14 | 15 | 15 |
| Congestive heart failure | 37 | 39 | 37 | 36 |
| Other cardiovascular disease | 15 | 14 | 15 | 16 |
| Cerebrovascular disease | 2 | 2 | 2 | 2 |
| Chronic obstructive pulmonary disease | 5 | 5 | 5 | 5 |
| History of malignancya | 2 | 2 | 2 | 2 |
| Medications | ||||
| Iron, median monthly dose | 333 (150–483) | 333 (150–500) | 333 (167–500) | 333 (133–467) |
| ESA, median weekly dose | 26,400 (16,500–36,300) | 26,400 (16,500–39,600) | 26,400 (16,500–37,500) | 24,750 (14,850–33,000) |
| Laboratory data | ||||
| Albumin, g/dla | 3.5±0.5 | 3.5±0.5 | 3.5±0.5 | 3.5±0.5 |
| Creatinine, mg/dl | 5.9±2.4 | 6.1±2.6 | 6.0±2.4 | 5.7±2.2 |
| Potassium, mEq/L | 4.4±0.5 | 4.4±0.5 | 4.4±0.5 | 4.4±0.5 |
| Sodium, mEq/L | 138±3 | 138±3 | 138±3 | 138±3 |
| Bicarbonate, mg/dl | 24±3 | 23±3 | 24±3 | 24±3 |
| Hemoglobin, g/dla | 11.1±1.2 | 11.1±1.2 | 11.2±1.2 | 11.1±1.2 |
| Ferritin, ng/ml | 282 (164–481) | 250 (147–425) | 272 (161–461) | 308 (179–528) |
| Total iron binding capacity, mg/dl | 225±49 | 229±51 | 227±48 | 22 3±48 |
| Iron saturation, % | 23±9 | 22±9 | 23±9 | 24±9 |
| Calcium, mg/dl | 9.1±0.6 | 9.1±0.6 | 9.1±0.6 | 9.1±0.6 |
| Phosphorus, mg/dl | 4.9±1.1 | 5.0±1.2 | 5.0±1.1 | 4.9±1.1 |
| Intact parathyroid hormone, pg/ml | 314 (198–486) | 327 (204–508) | 318 (204–487) | 305 (191–473) |
| Alkaline phosphatase, U/L | 87 (69–115) | 86 (68–113) | 86 (68–113) | 88 (70–116) |
| WBC, ×103/μla | 7.8±2.7 | 7.8±2.7 | 7.8±2.8 | 7.8±2.6 |
| Lymphocytes, % of total WBCsa | 21±8 | 21±7 | 21±7 | 21±8 |
Data are presented as mean±SD, median (interquartile range), or percentage. Values presented are from the first 91-day period after initiation of in-center hemodialysis. stdKt/V, standard Kt/V; CVC, central venous catheter; AV, arteriovenous; iv, intravenous; ESA, erythropoiesis stimulating agent; WBC, white blood cell.
a
Indicates P>0.001 for the difference among stdKt/V categories using ANOVA, a Kruskal–Wallis test, or a chi-squared test. P<0.001 for all other comparisons.